Vident Investment Advisory, LLC Alaunos Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 17, 2020	SELL	$2.2 - $3.71 $635,278 - $1.07 Million	-288,763 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$1.9 - $4.98 $34,243 - $89,754	-18,023 Reduced 5.87%	288,763 $707,000
Q4 2019 Feb 11, 2020	BUY	$3.95 - $5.35 $141,868 - $192,150	35,916 Added 13.26%	306,786 $1.45 Million
Q3 2019 Nov 13, 2019	SELL	$4.13 - $6.94 $31,962 - $53,708	-7,739 Reduced 2.78%	270,870 $1.16 Million
Q2 2019 Aug 12, 2019	BUY	$3.98 - $6.2 $1.11 Million - $1.73 Million	278,609 New	278,609 $1.62 Million
Q4 2018 Feb 14, 2019	SELL	$1.61 - $3.62 $886,399 - $1.99 Million	-550,559 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$2.26 - $3.27 $82,932 - $119,995	-36,696 Reduced 6.25%	550,559 $1.76 Million
Q2 2018 Aug 14, 2018	BUY	$3.02 - $4.94 $565,328 - $924,743	187,195 Added 46.79%	587,255 $1.77 Million
Q1 2018 May 14, 2018	BUY	$3.46 - $5.14 $370,143 - $549,866	106,978 Added 36.5%	400,060 $1.74 Million
Q4 2017 Feb 15, 2018	BUY	$4.0 - $6.54 $327,760 - $535,887	81,940 Added 38.81%	293,082 $1.21 Million
Q3 2017 Nov 14, 2017	BUY	$4.99 - $6.57 $1.05 Million - $1.39 Million	211,142	211,142 $1.3 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.